Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bluebird Bio (NQ: BLUE )

3.010 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 18
Open 3.010
Bid (Size) 2.910 (3)
Ask (Size) 3.010 (39)
Prev. Close 3.010
Today's Range 3.010 - 3.010
52wk Range 2.780 - 8.580
Shares Outstanding 67,578,549
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cathie Wood Is Buying This Growth Stock Hand Over Fist Lately. Should You Follow Her Lead?
The Internet's most famous innovation-focused investor is excited about this company's innovative approach to editing the human genome. 
Via The Motley Fool
Where Will Bluebird Bio Be in 1 Year?
Things could get better for the biotech, but they could also get worse. 
Via The Motley Fool

Performance

YTD
-56.63%
-56.63%
1 Month
-18.87%
-18.87%
3 Month
-9.61%
-9.61%
6 Month
-3.53%
-3.53%
1 Year
-50.90%
-50.90%

More News

Read More
Fisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
Are Gene Therapy Stocks The Market's Next Big Winners?
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
1 Beaten-Down Stock That Could Soar by 89%, According to Wall Street
Via The Motley Fool
Better Growth Stock: CRISPR Therapeutics vs. Bluebird Bio
Via The Motley Fool
1 Huge Risk That Gene-Editing Stock Investors Desperately Need to Know
Via The Motley Fool
Have Million-Dollar Gene Therapies Finally Reached An Inflection Point?
Via Investor's Business Daily
Exposures Product Safety
More Likely to 5x First: Bluebird Bio vs. CRISPR Therapeutics
Via The Motley Fool
2 Growth Stocks That Could Rocket 88% to 99% Higher According to Wall Street
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
Via Benzinga
bluebird bio Announces September Investor Events
From bluebird bio, Inc.
Via Business Wire
Is Bluebird Bio a Bargain Buy in September?
Via The Motley Fool
Wall Street Thinks This Tiny Biotech Company Could Soar Soon
Via The Motley Fool
1 Beaten-Down Growth Stock You'd Regret Not Buying on the Dip, According to Wall Street
Via The Motley Fool
7 Very Oversold Nasdaq Stocks to Buy Right Now
Via InvestorPlace
bluebird bio Confirms That FDA Has Communicated That Advisory Committee Meeting Will Not Be Scheduled for lovo-cel Gene Therapy for Sickle Cell Disease
From bluebird bio, Inc.
Via Business Wire
Fox, Warner Music, Eli Lilly, Chegg And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
bluebird bio Reports Second Quarter 2023 Financial Results and Highlights Operational Progress
From bluebird bio, Inc.
Via Business Wire
2 Magnificent Growth Stocks I'm Buying Hand Over Fist Right Now
Via The Motley Fool
3 Stocks to Buy for Lottery Jackpot Style Returns
Via InvestorPlace
bluebird bio to Host Second Quarter 2023 Financial Results Conference Call and Provide Commercial Update
From bluebird bio, Inc.
Via Business Wire
3 Small-Cap Stocks That Could Be Big-Time Winners
Via The Motley Fool
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Amarin Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.